Nevertheless, most cGAS-STING signaling pathway agonists have not yet encountered cancer-promoting effects, as only a few doses of treatment can lead to a burst production of type I IFN, which activates the anti-cancer immune system (Flood et al., 2019). This evidence concerns the gene CGAS and cancer.